SITC 2024 | Oncolytic virus therapy + neoadjuvant chemo shows promise for bladder cancer response & preservation
Roger Li
• 7 Nov 2024
Roger Li, MD, H Lee Moffitt Cancer Center, Tampa, FL, comments on the potential of combining oncolytic virus therapy with neoadjuvant chemotherapy for bladder cancer, highlighting the feasibility of preserving the bladder in patients achieving a pathologic complete response. Dr Li suggests that this approach could further increase response rates and improve patient outcomes, particularly in terms of bladder preservation. This interview took place at the SITC 2024 congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
